Jci_page_head_homepage_01 Jci_page_head_homepage_02
Hiroshi Harada, Alan D. Salama, Masayuki Sho, Atsushi Izawa, Sigrid E. Sandner, Toshiro Ito, Hisaya Akiba, Hideo Yagita, Arlene H. Sharpe, Gordon J. Freeman, Mohamed H. Sayegh
Published in Volume 112, Issue 2
J Clin Invest. 2003; 112(2):234–243 doi:10.1172/JCI17008
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 8

The interaction between the CD28/CTLA-4-B7 pathway and ICOS-B7h signal blockade. (a) CD28-deficient C57BL/6 recipients of a BALB/c heart all ultimately rejected their grafts (MST, 16 days). CD28-deficient recipients treated with early (MST, 31 days) or delayed (MST, 70 days) ICOS-B7h blockade had prolonged graft survival as compared with untreated controls (P = 0.0122 for early treatment as compared with controls and P = 0.0008 for delayed treatment as compared with controls), with delayed treatment resulting in significantly prolonged survival as compared with early blockade (P = 0.0089 for delayed as compared with early blockade). (b and c) Anti–CTLA-4 mAb was used in conjunction with anti-ICOS mAb. Vascularized C57BL/6 hearts were transplanted into BALB/c recipients. Anti–CTLA-4 treatment alone accelerated allograft rejection (MST, 7 days; n = 4; P < 0.005 as compared with untreated control). Anti–CTLA-4 abrogated the prolongation of allograft survival in the recipients of early (b) or delayed anti-ICOS mAb (c) treatment (MST, 7 and 6 days; n = 5; P < 0.005 and P < 0.0001, respectively) as compared with recipients of early or delayed anti-ICOS mAb treatment.